Sanofi has divested two OTC brands to Italy’s Angelini SPA in a deal worth €47m ($51m). The French firm signaled earlier this year that it would continue to rationalize its Consumer Healthcare portfolio to focus its efforts around a number of priority brands and categories. (Also see "Sanofi Plans Further Consumer Health Divestments As It Reports Slow Start To Year" - HBW Insight, 29 April, 2019.)
Angelini has picked up the BoxaGrippal (ibuprofen/pseudoephedrine) cold and flu brand and the Heumann range of medicinal teas indicated to...
